Unlock your metabolic health and
weight loss potential with
Discover our revolutionary GLP-1, GLP-1/GIP program, expertly crafted to support your journey to a healthier, happier you. Our dedicated team will guide you every step of the way.
Schedule a consultation and see if you qualify for our program. We partner only with top-notch 503A and 503B pharmacies to ensure seamless delivery of our premium compounded medicines, directly to your door.
Prescription ingredients
for personalized care.
Semaglutide and Tirzepatide facilitate significant weight loss by reducing appetite and slowing gastric emptying. These medications also reduce the risk of cardiovascular events, such as heart attacks and strokes. With a low risk of hypoglycemia, they act primarily in response to elevated blood sugar levels. Additionally, they may help reduce liver fat and improve liver function, offering potential benefits.
Looking to shed some
pounds?
We've got you covered! Lose weight with GLP-1s.
Weight loss treatment from
Frequently asked questions
Get StartedTransformations
Transformation after taking GLP-1, GLP-1/GIP agonists medication
Transformation after taking GLP-1, GLP-1/GIP agonists medication
Access to licensed providers
Ongoing care comes from an experienced Care Team and vetted providers specializing in weight loss—at no extra cost.
Tailored dosage regimens
Dosage plans are tailored to your specific weight loss goals and preferences.
Fast and free shipping
Temperature-controlled shipping ensures optimal preservation of medication by maintaining the required temperature throughout transit.
IMPORTANT SAFETY INFORMATION
COMPOUNDED SEMAGLUTIDE and TIRZEPATIDE are glucagon-like peptide-1 (GLP-1), GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonists indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight or obesity).
Limitations of Use: Co-administration of COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE or any other GLP-1 receptor agonists is not recommended. The safety and efficacy of coadministration with other products for weight management have not been established. COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE has not been studied in patients with a history of pancreatitis.
- In rodents, SEMAGLUTIDE/TIRZEPATIDE causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of SEMAGLUTIDE/TIRZEPATIDE-induced rodent thyroid C-cell tumors has not been determined.
- SEMAGLUTIDE/TIRZEPATIDE is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
Do not take COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Have been diagnosed with Diabetes (Type 1 or 2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Have a diagnosis or history of gastroparesis - severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.
- Have a known allergy to semaglutide/tirzepatide or any other GLP-1 medication or any of the inactive ingredients in COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE. Inactive ingredients include: di-sodium hydrogen phosphate dihydrate, sodium chloride, benzyl alcohol, hydrochloric acid, sodium hydroxide pellets, and water.
- Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS
- Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
- Gastroparesis: Uncommon, but more serious gastrointestinal adverse effects may also occur more frequently with GLP-1, GLP-1/GIP receptor agonists than with other weight loss agents.
- Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
- Acute Kidney Injury: Has occurred. Monitor renal function when initiating or escalating doses of COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions.
- Hypersensitivity Reactions: Anaphylactic reactions and angioedema have been reported postmarketing. Discontinue COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE if suspected and promptly seek medical advice.
- Females and Males of Reproductive Potential: Discontinue COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE at least 2 months before a planned pregnancy because of the long half-life of these medications.
- Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE immediately.
- Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has been reported in trials with GLP-1, GLP-1/GIP agonists. Patients with a history of diabetic retinopathy should be monitored.
- Heart Rate Increase: Monitor heart rate at regular intervals.
- Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE if symptoms develop.
- A recent study suggested a possible connection between semaglutide/tirzepatide use and increased risk for a blinding eye disease called non-arteritic anterior ischemic optic neuropathy (NAION). There isn't enough data yet to suggest patients should be concerned or stop taking their medications. Further research is necessary to confirm the hypothesis. Patients should make an informed choice based on individual risk.
- Side Effects: Common side effects (≥5% incidence) include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia (in type 2 diabetes patients), flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.
- To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
- Medication Interactions: COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.
- Use in Specific Populations: Pregnancy - May cause fetal harm. When pregnancy is recognized, discontinue COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE.
- Females and Males of Reproductive Potential: Discontinue COMPOUNDED SEMAGLUTIDE/TIRZEPATIDE at least 2 months before a planned pregnancy because of the long half-life of these medications.
- Due to the the delayed gastric emptying associated with the use of GLP-1, GLP-1/GIP agonist, discontinue these medications at least 2 weeks prior to any elective surgery.
